Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioCorRx Inc.BICX · Entity 8179 | Director · CEO and CFO | April 24, 2024 | January 31, 2025 |
| Change Agents Corporation.ALBT · Entity 8466 | Director | June 29, 2026 | July 13, 2026 |
| Functional Brands Inc.MEHA · Entity 8693 | Director | November 05, 2025 | December 05, 2025 |
| La Rosa Holdings Corp.LRHC · Entity 8569 | Director | August 11, 2025 | August 19, 2025 |
| NOMAD POWER SOLUTIONS, INC.LIXT · Entity 6975 | Director | July 01, 2026 | July 02, 2026 |
| Powell Max LtdPMAX. · Entity 8546 | Director | March 10, 2026 | May 14, 2026 |
| Vocodia Holdings CorpVOCO · Entity 8609 | Director | February 14, 2024 | February 24, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioCorRx Inc.
Report date April 24, 2024 · Filed January 31, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001SEC Table I · non-derivative | Direct | 843,578 |
Ending reported balance
After 2024-12-31 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2024-04-24 · Grant · Acquired 224,196 · Balance 314,795 F1: These shares were issued to Ms. Felix pursuant to an Exchange Agreement (the "April 2024 Exchange Agreement") by and between BioCorRx Inc. (the "Company") and Ms. Felix dated April 24, 2024. Pursuant to the April 2024 Exchange Agreement, Ms. Felix agreed to the exchange of directors fees in the amount of $265,000 for 224,196 shares of the Company's common stock, par value $0.001 per share (the "Common Stock") at a price of $1.18 per share based on the underlying value of the Common Stock at the date of issuance. Row 2 · 2024-07-02 · Grant · Acquired 500,000 · Balance 814,795 F2: These shares were issued to Ms. Felix pursuant to a Stock Grant Award Agreement (the "Award Agreement") by and between the Company and Ms. Felix, dated July 2, 2024. Pursuant to the Award Agreement, in recognition of Ms. Felix's services to the Company, and for assuming additional responsibilities, the Company issued 500,000 shares of Common Stock to Ms. Felix, representing an amount equal to $235,000, or $0.32 per share based on the closing price of the Common Stock on the date of issuance. These shares are subject to lock-up obligations for a period of 180 days following the date on which the Company's securities become listed for trading on a national securities exchange. F3: These shares are subject to lock-up obligations for a period of 180 days following the effective date of a registration statement of the Company filed under the Securities Act of 1933, as amended, pursuant to which the Company's securities become listed for trading on a national securities exchange or such longer period to facilitate compliance with FINRA Rule 2241 or any successor or similar rule or regulation. Row 3 · 2024-09-30 · Grant · Acquired 15,625 · Balance 830,420 F4: These shares were issued to Ms. Felix pursuant to a Director Agreement (the "Director Agreement"), dated March 1, 2019, by and between the Company and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of Common Stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.32. Row 4 · 2024-12-31 · Grant · Acquired 13,158 · Balance 843,578 F5: These shares were issued to Ms. Felix pursuant to the Director Agreement. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of Common Stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.38. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued to Ms. Felix pursuant to an Exchange Agreement (the "April 2024 Exchange Agreement") by and between BioCorRx Inc. (the "Company") and Ms. Felix dated April 24, 2024. Pursuant to the April 2024 Exchange Agreement, Ms. Felix agreed to the exchange of directors fees in the amount of $265,000 for 224,196 shares of the Company's common stock, par value $0.001 per share (the "Common Stock") at a price of $1.18 per share based on the underlying value of the Common Stock at the date of issuance.
F2: These shares were issued to Ms. Felix pursuant to a Stock Grant Award Agreement (the "Award Agreement") by and between the Company and Ms. Felix, dated July 2, 2024. Pursuant to the Award Agreement, in recognition of Ms. Felix's services to the Company, and for assuming additional responsibilities, the Company issued 500,000 shares of Common Stock to Ms. Felix, representing an amount equal to $235,000, or $0.32 per share based on the closing price of the Common Stock on the date of issuance. These shares are subject to lock-up obligations for a period of 180 days following the date on which the Company's securities become listed for trading on a national securities exchange.
F3: These shares are subject to lock-up obligations for a period of 180 days following the effective date of a registration statement of the Company filed under the Securities Act of 1933, as amended, pursuant to which the Company's securities become listed for trading on a national securities exchange or such longer period to facilitate compliance with FINRA Rule 2241 or any successor or similar rule or regulation.
F4: These shares were issued to Ms. Felix pursuant to a Director Agreement (the "Director Agreement"), dated March 1, 2019, by and between the Company and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of Common Stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.32.
F5: These shares were issued to Ms. Felix pursuant to the Director Agreement. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of Common Stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.38.
Change Agents Corporation.
Report date June 29, 2026 · Filed July 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.28 · Expires 2029-06-29 | Direct | 101,586 |
Reported balance
After 2026-06-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-29 · Grant · Acquired 100,000 · Balance 101,586 F1: One hundred percent (100%) of the shares subject to the Option shall vest in full on the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: One hundred percent (100%) of the shares subject to the Option shall vest in full on the grant date.
Functional Brands Inc.
Report date November 05, 2025 · Filed December 05, 2025
This filing explicitly reported no securities owned.
La Rosa Holdings Corp.
Report date August 11, 2025 · Filed August 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 600 |
Reported balance
After 2025-08-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-08-11 · Grant · Acquired 600 · Balance 600 F1: Represents shares of restricted common stock, vesting on the date of the grant, granted pursuant to the Second Amended and Restated La Rosa Holdings Corp. 2022 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of restricted common stock, vesting on the date of the grant, granted pursuant to the Second Amended and Restated La Rosa Holdings Corp. 2022 Equity Incentive Plan.
NOMAD POWER SOLUTIONS, INC.
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55,000 |
Reported balance
After 2026-07-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 30,000 · Balance 55,000 F1: The reported transaction involved the Reporting Person's receipt of 30,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 30,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied. F2: The total reported in Column 5 includes (i) the 30,000 newly awarded RSUs, and (ii) 25,000 RSUs, all of which have vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction involved the Reporting Person's receipt of 30,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 30,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied.
F2: The total reported in Column 5 includes (i) the 30,000 newly awarded RSUs, and (ii) 25,000 RSUs, all of which have vested.
Powell Max Ltd
Report date March 10, 2026 · Filed May 14, 2026
This filing explicitly reported no securities owned.
Vocodia Holdings Corp
Report date February 14, 2024 · Filed February 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,000 |
Reported balance
Holding disclosure · report date 2024-02-14 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 5,000 F1: Represents the vesting of 25% of the 20,000 RSUs issued on the Effective Date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-02-14 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: Pursuant to her Board of Directors Agreement, Mrs. Lourdes Felix shall receive an award of 20,000 RSUs on the Effective Date. The RSUs shall vest with respect to 25% of the total number of RSUs on the Effective Date and after 25% thereafter every three (3) month anniversary of the Effective Date until fully vested on the 3rd anniversary of the Effective Date, her continuous service to the Company through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the vesting of 25% of the 20,000 RSUs issued on the Effective Date.
F2: Pursuant to her Board of Directors Agreement, Mrs. Lourdes Felix shall receive an award of 20,000 RSUs on the Effective Date. The RSUs shall vest with respect to 25% of the total number of RSUs on the Effective Date and after 25% thereafter every three (3) month anniversary of the Effective Date until fully vested on the 3rd anniversary of the Effective Date, her continuous service to the Company through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 2, 2026 20:08 UTC | NOMAD POWER SOLUTIONS, INC. LIXT · Entity 6975 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-031882 · ownership.xml · nonDerivative · entry 1 Felix Lourdes · CIK 0001569735 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 F1 · shares: The reported transaction involved the Reporting Person's receipt of 30,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 30,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied. F2 · balance_after: The total reported in Column 5 includes (i) the 30,000 newly awarded RSUs, and (ii) 25,000 RSUs, all of which have vested. Read SEC document |
| June 29, 2026 Filed Jul 13, 2026 20:30 UTC | Change Agents Corporation. ALBT · Entity 8466 | GrantOptions (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0001213900-26-077588 · ownership.xml · derivative · entry 1 Felix Lourdes · CIK 0001569735 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,586 Underlying: Common Stock · 100,000 shares Expires 2029-06-29 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the Option shall vest in full on the grant date. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:15 UTC | NOMAD POWER SOLUTIONS, INC. LIXT · Entity 6975 | Disposition to issuerStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $4.05 | Not disclosed |
DisclosureSEC source: 0001493152-26-017852 · ownership.xml · derivative · entry 2 Felix Lourdes · CIK 0001569735 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2030-12-24 F1 · price: On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 25,000 options (the "Options") granted to the Reporting Person on December 24, 2025. In exchange for the Options, the Reporting Person received 25,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 25,000 RSUs vest immediately upon grant. F2 · derivative.exercise_date: The canceled Options provided for vesting 50% on the grant date, the remaining 50% vesting in equal installments of 12.5% on March 31, 2026 and on the last date of each subsequent calendar quarter thereafter until fully vested. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:15 UTC | NOMAD POWER SOLUTIONS, INC. LIXT · Entity 6975 | GrantCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-017852 · ownership.xml · nonDerivative · entry 1 Felix Lourdes · CIK 0001569735 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 F1 · price: On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 25,000 options (the "Options") granted to the Reporting Person on December 24, 2025. In exchange for the Options, the Reporting Person received 25,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 25,000 RSUs vest immediately upon grant. Read SEC document |
| December 24, 2025 Filed Dec 30, 2025 00:19 UTC | NOMAD POWER SOLUTIONS, INC. LIXT · Entity 6975 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001493152-25-029459 · ownership.xml · derivative · entry 1 Felix Lourdes · CIK 0001569735 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-12-24 F1 · derivative.exercise_date: Fifty percent (50%) of the option vested and became exercisable on the grant date. The remaining fifty percent (50%) vests in equal installments of twelve and one-half percent (12.5%) on March 31, 2026 and on the last date of each subsequent calendar quarter thereafter until fully vested, subject to the reporting person's continuous service through each applicable vesting date. Read SEC document |
| August 11, 2025 Filed Aug 19, 2025 01:01 UTC | La Rosa Holdings Corp. LRHC · Entity 8569 | GrantCommon Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-078102 · ownership.xml · nonDerivative · entry 1 Felix Lourdes · CIK 0001569735 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600 F1 · security: Represents shares of restricted common stock, vesting on the date of the grant, granted pursuant to the Second Amended and Restated La Rosa Holdings Corp. 2022 Equity Incentive Plan. Read SEC document |
| December 31, 2024 Filed Jan 31, 2025 13:50 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 13,158 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-000576 · form4.xml · nonDerivative · entry 4 Felix Lourdes · CIK 0001569735 · Director · CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 843,578 F5 · kind: These shares were issued to Ms. Felix pursuant to the Director Agreement. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of Common Stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.38. Read SEC document |
| September 30, 2024 Filed Jan 31, 2025 13:50 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 15,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-000576 · form4.xml · nonDerivative · entry 3 Felix Lourdes · CIK 0001569735 · Director · CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 830,420 F4 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement (the "Director Agreement"), dated March 1, 2019, by and between the Company and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of Common Stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.32. Read SEC document |
| July 02, 2024 Filed Jan 31, 2025 13:50 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-000576 · form4.xml · nonDerivative · entry 2 Felix Lourdes · CIK 0001569735 · Director · CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 814,795 F2 · kind: These shares were issued to Ms. Felix pursuant to a Stock Grant Award Agreement (the "Award Agreement") by and between the Company and Ms. Felix, dated July 2, 2024. Pursuant to the Award Agreement, in recognition of Ms. Felix's services to the Company, and for assuming additional responsibilities, the Company issued 500,000 shares of Common Stock to Ms. Felix, representing an amount equal to $235,000, or $0.32 per share based on the closing price of the Common Stock on the date of issuance. These shares are subject to lock-up obligations for a period of 180 days following the date on which the Company's securities become listed for trading on a national securities exchange. F3 · kind: These shares are subject to lock-up obligations for a period of 180 days following the effective date of a registration statement of the Company filed under the Securities Act of 1933, as amended, pursuant to which the Company's securities become listed for trading on a national securities exchange or such longer period to facilitate compliance with FINRA Rule 2241 or any successor or similar rule or regulation. Read SEC document |
| June 28, 2024 Filed Jul 8, 2024 19:47 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 10,204 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-004103 · form4.xml · nonDerivative · entry 1 Felix Lourdes · CIK 0001569735 · Director · CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,599 F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.49. Read SEC document |
| April 24, 2024 Filed Jan 31, 2025 13:50 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 224,196 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-000576 · form4.xml · nonDerivative · entry 1 Felix Lourdes · CIK 0001569735 · Director · CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 314,795 F1 · kind: These shares were issued to Ms. Felix pursuant to an Exchange Agreement (the "April 2024 Exchange Agreement") by and between BioCorRx Inc. (the "Company") and Ms. Felix dated April 24, 2024. Pursuant to the April 2024 Exchange Agreement, Ms. Felix agreed to the exchange of directors fees in the amount of $265,000 for 224,196 shares of the Company's common stock, par value $0.001 per share (the "Common Stock") at a price of $1.18 per share based on the underlying value of the Common Stock at the date of issuance. Read SEC document |
| March 28, 2024 Filed Apr 3, 2024 10:05 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 5,566 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-001806 · form4.xml · nonDerivative · entry 1 Felix Lourdes · CIK 0001569735 · Director · CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,395 F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.90. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 22:00 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 6,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-000043 · form4.xml · nonDerivative · entry 1 Felix Lourdes · CIK 0001569735 · Director · CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,829 F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.81. Read SEC document |
| September 29, 2023 Filed Oct 2, 2023 20:30 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 2,858 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-007294 · primary_doc.xml · nonDerivative · entry 1 Felix Lourdes · CIK 0001569735 · Director · CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,656 F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.75. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:03 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 2,891 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-005016 · form4.xml · nonDerivative · entry 1 Felix Lourdes · CIK 0001569735 · Director · CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,798 F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.73. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 22:28 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 2,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-002224 · form4.xml · nonDerivative · entry 1 Felix Lourdes · CIK 0001569735 · Director · CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,907 F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.77. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:15 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 5,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-000087 · form4.xml · nonDerivative · entry 1 Felix Lourdes · CIK 0001569735 · Director · CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,083 F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.94. Read SEC document |
| September 30, 2022 Filed Oct 5, 2022 19:48 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 2,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-007465 · form4.xml · nonDerivative · entry 1 Felix Lourdes · CIK 0001569735 · Director · CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,764 F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.04. Read SEC document |
| June 30, 2022 Filed Jul 7, 2022 22:06 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 2,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-004883 · form4.xml · nonDerivative · entry 1 Felix Lourdes · CIK 0001569735 · Director · CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,314 F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.39. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:29 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 1,408 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-002037 · form4.xml · nonDerivative · entry 1 Felix Lourdes · CIK 0001569735 · Director · CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,222 F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $3.55. Read SEC document |
| December 31, 2021 Filed Mar 2, 2022 20:14 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 1,141 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-001168 · form4.xml · nonDerivative · entry 1 Felix Lourdes · CIK 0001569735 · Director · CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,814 F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $4.38. Read SEC document |
| September 30, 2021 Filed Oct 25, 2021 20:07 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 1,381 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-21-007562 · form4.xml · nonDerivative · entry 1 Felix Lourdes · CIK 0001569735 · Director · CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,673 F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $3.62. Read SEC document |
| June 30, 2021 Filed Jul 7, 2021 00:23 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 1,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-21-004470 · form4.xml · nonDerivative · entry 1 Felix Lourdes · CIK 0001569735 · Director · CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,292 F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $4.13. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 15:52 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 2,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-21-002006 · form4.xml · nonDerivative · entry 1 Felix Lourdes · CIK 0001569735 · Director · CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,082 F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.15. Read SEC document |
| September 30, 2020 Filed Oct 13, 2020 22:35 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 2,631 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-20-005860 · form4.xml · nonDerivative · entry 1 Felix Lourdes · CIK 0001569735 · Director · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,855 F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.90. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.